<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945580</url>
  </required_header>
  <id_info>
    <org_study_id>U9920</org_study_id>
    <secondary_id>AUGS PFD Outcome Registry</secondary_id>
    <nct_id>NCT01945580</nct_id>
  </id_info>
  <brief_title>Xenform Postmarket Surveillance Study</brief_title>
  <acronym>Xenform</acronym>
  <official_title>A Prospective, Non-Randomized, Parallel Cohort, Multi-Center Study of Xenform vs. Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare transvaginal repair with a biologic graft to traditional native tissue repair in&#xD;
      women surgically treated for anterior and/or apical pelvic organ prolapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate clinical effectiveness of transvaginal repair with&#xD;
      Xenform against traditional native tissue repair in women surgically treated for anterior&#xD;
      and/or apical pelvic organ prolapse. Secondary objectives are to evaluate Xenform-related&#xD;
      complications and subject reported outcomes.&#xD;
&#xD;
      The primary endpoint of the study is to achieve non-inferiority of transvaginal repair with&#xD;
      Xenform over native tissue repair at 36 months as compared to baseline. Success will be based&#xD;
      on a composite of objective and subjective measures.&#xD;
&#xD;
      Additionally, a co-primary endpoint of the study is to achieve non-inferiority of&#xD;
      transvaginal repair with Xenform to native tissue repair for safety by comparing rates of&#xD;
      serious device or serious procedure related complications between baseline and the 36 month&#xD;
      time point.&#xD;
&#xD;
      The secondary endpoints of the study include assessments of complications and subject&#xD;
      reported outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2014</start_date>
  <completion_date type="Actual">February 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Success at 36 Months</measure>
    <time_frame>36 Months</time_frame>
    <description>The primary endpoint of the study was to achieve non-inferiority of transvaginal repair with Xenform over NTR at 36 months as compared to baseline. Success was based on a composite of objective and subjective measures.&#xD;
Subjective success was achieved if the patient denied symptoms of vaginal bulging per Pelvic Floor Distress Inventory (PFDI-20) question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (&lt; 2).&#xD;
Anatomic success (in the operated compartment):&#xD;
Anterior segment: Leading edge of anterior prolapse was at or above the hymen or Pelvic Organ Prolapse Quantification System (POP-Q) point Ba ≤ 0.&#xD;
Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C &lt; -1/2 TVL) for multi-compartment prolapse or POP-Q point C ≤ 0 for single compartment apical prolapse.&#xD;
No retreatment for POP: no additional surgical treatment for POP in the segment(s) of the vagina treated at the index surgery or no pessary use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Device-related and/or Procedure-Related Adverse Events</measure>
    <time_frame>36 months</time_frame>
    <description>Co-primary endpoint of the study was to achieve non-inferiority of transvaginal mesh repair with Xenform to NTR for safety by comparing rates of serious device-related or serious procedure-related complications between baseline and the 36-month time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mesh Erosion</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of Mesh Erosion at 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mesh Exposure</measure>
    <time_frame>36 Months</time_frame>
    <description>Incidence of mesh exposure at 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With de Novo Dyspareunia</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of de novo dyspareunia at 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Specific Outcomes Measured With the Pelvic Floor Impact Questionnaire (PFIQ-7)]</measure>
    <time_frame>36 months</time_frame>
    <description>Improvement in subject specific outcomes at 36 months compared to baseline [quality of life (QOL) per the Pelvic Floor Impact Questionnaire (PFIQ-7)]&#xD;
The PFIQ-7 is composed of three separate but related assessments: the UIQ-7 addresses the impact of urinary incontinence symptoms, the CRAIQ-7 addresses the impact of colorectal-anal or bowel symptoms, and the POPIQ-7 addresses impact of vaginal and pelvic symptoms. For each question, the low score (0) corresponds to &quot;not at all&quot; and the high score (3) corresponds to &quot;quite a bit&quot;. The scores for the UIQ-7, CRAIQ-7 and POPIQ-7 are additive to yield the final PFIQ-7 score. The scale scores are then added together to get the total PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.&#xD;
Reported score is change from baseline at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Specific Outcomes Measured by the Pelvic Floor Symptoms Per the Pelvic Floor Distress Inventory (PFDI-20)</measure>
    <time_frame>36 months</time_frame>
    <description>Improvement in subject specific outcomes at 36 months compared to baseline [pelvic floor symptoms per the Pelvic Floor Distress Inventory (PFDI-20)]&#xD;
The Pelvic Floor Distress Inventory-20 (PFDI-20) is complimentary to the PFIQ-7 and focuses on symptoms of distress in the same compartmentalized fashion as the PFIQ-7. Like the PFIQ-7, the PFDI-20 consists of three components: Urinary Distress Inventory (UDI; 6 questions), the Pelvic Organ Prolapse Distress Inventory (POPDI; 6 questions), and Colorectal-Anal Distress Inventory (CRADI; 8 questions). The scoring for the PFDI-20 is similar to the PFIQ-7 where each individual component score is summed. The total ranges from 0 to 300 with a higher score indicating a greater impact to QOL (i.e., distress symptoms are more noticeable) and a lower score indicating a lesser impact to QOL (i.e., distress symptoms are less noticeable).&#xD;
The reported result is change from baseline at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Specific Outcomes Measured by the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)</measure>
    <time_frame>36 months</time_frame>
    <description>Improvement in subject specific outcomes at 36 months compared to baseline [change in sexual functioning per the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)]&#xD;
This is a self-administered questionnaire and the responses are graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Values range from 0 to 48 and a higher score indicates better sexual function.&#xD;
The reported result is change from baseline at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Specific Outcomes: Pain Measured by the TOMUS Pain Scale</measure>
    <time_frame>36 months</time_frame>
    <description>Improvement in subject specific outcomes at 36 months compared to baseline [pain per the TOMUS pain scale]&#xD;
The TOMUS Pain Score, a visual analog instrument with a scale of 0 (no pain sensation) to 10 (most intense pain sensation imaginable), was used to assess pain associated with surgery for pelvic organ prolapse in this study. There are seven (7) questions each with a maximum score of 10 and a possible score range of 0-70).&#xD;
The reported results are change from baseline at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Improvement Measured by the Patient Global Impression of Improvement for Prolapse (PGI-I)</measure>
    <time_frame>36 months</time_frame>
    <description>Assessment of subject's level of improvement, measured by the Patient Global Impression of Improvement for Prolapse (PGI-I)&#xD;
The Patient Global Impression of Improvement (PGI-I) for prolapse symptoms is a validated QOL instrument that assesses patient perception of overall improvement after surgical interventions for POP.12 The scale rates the patient's improvement or worsening of prolapse symptoms relative to baseline. The scale is as follows: 1- Very much better; 2- Much better; 3- A little better; 4- No change; 5- A little worse; 6- Much worse; 7- Very much worse. Assessments were performed at 6-month intervals beginning 6 months after the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Re-Intervention or Re-Surgery</measure>
    <time_frame>36 months</time_frame>
    <description>Absence of re-intervention or re-surgery for recurrence or persistence of POP or Xenform exposure/erosion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Success</measure>
    <time_frame>36 months</time_frame>
    <description>Surgical success based on the following composite outcome:&#xD;
Subjective success: Patient denied symptoms of vaginal bulging per PFDI-20 question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (˂ 2)&#xD;
Anatomic success (in the operated compartment):&#xD;
Anterior Segment: No anterior prolapse at or beyond the hymen or POP-Q point Ba ˂ 0&#xD;
Apical Segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C ˂ 1/2 TVL) for multi-compartment prolapse or POP-Q point C ˂ 0 for prolapse of the apical compartment alone&#xD;
No retreatment for POP (treated segment): No additional surgical treatment for POP in the segment(s) of the vagina treated at the index surgery or no pessary use since index surgery ('treated segment' refers to the target compartments in this study, which are the anterior and apical compartments)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Complications</measure>
    <time_frame>36 Months</time_frame>
    <description>Incidence of the following device-related or procedure-related adverse events (AEs): pelvic pain, infection, vaginal shortening, atypical vaginal discharge, neuromuscular problems, vaginal scarring, de novo vaginal bleeding, fistula formation and/or de novo voiding dysfunction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Xenform</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prolapse Repair with Native Tissue Only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prolapse Repair</intervention_name>
    <description>Transvaginal anterior/apical pelvic organ prolapse repair</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Xenform</arm_group_label>
    <other_name>Transvaginal</other_name>
    <other_name>Prolapse</other_name>
    <other_name>POP Repair</other_name>
    <other_name>Anterior</other_name>
    <other_name>Apical</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is female&#xD;
&#xD;
          -  Subject is at least 18 years of age&#xD;
&#xD;
          -  Subject has pelvic organ prolapse with the leading edge at or beyond the hymen. At or&#xD;
             beyond the hymen is defined as POP-Q scores of Ba≥0 (for prolapse of the anterior&#xD;
             compartment alone) or C≥0 (for prolapse of the apical compartment alone) or C≥-1/2 TVL&#xD;
             and Ba≥0 (for a multi-compartment prolapse that includes the anterior and apical&#xD;
             compartments).&#xD;
&#xD;
          -  Subject reports a bothersome bulge they can see or feel per PFDI-20, question 3,&#xD;
             response of 2 or higher (i.e., responses of &quot;somewhat&quot;, &quot;moderately&quot;, or &quot;quite a&#xD;
             bit&quot;)&#xD;
&#xD;
          -  Subject or subject's legally authorized representative is willing to provide written&#xD;
             informed consent&#xD;
&#xD;
          -  Subject is willing and able to comply with the follow-up regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant or intends to become pregnant during the study&#xD;
&#xD;
          -  Subject has an active or chronic systemic infection including any gynecologic&#xD;
             infection, untreated urinary tract infection (UTI) or tissue necrosis&#xD;
&#xD;
          -  Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder,&#xD;
             colo-rectal or cervical)&#xD;
&#xD;
          -  Subject has had prior or is currently undergoing radiation, laser therapy, or&#xD;
             chemotherapy in the pelvic area&#xD;
&#xD;
          -  Subject has taken systemic steroids (within the last month), or immunosuppressive or&#xD;
             immunomodulatory treatment (within the last 3 months)&#xD;
&#xD;
          -  Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus&#xD;
             erythematosus (SLE), Marfan syndrome, Ehlers Danlos, collagenosis, polymyositis,&#xD;
             polymyalgia rheumatica)&#xD;
&#xD;
          -  Subject has chronic systemic pain that includes the pelvic area or chronic focal pain&#xD;
             that involves the pelvis&#xD;
&#xD;
          -  Subject has uncontrolled diabetes mellitus (DM)&#xD;
&#xD;
          -  Subject has a known neurologic or medical condition affecting bladder function (e.g.,&#xD;
             multiple sclerosis, spinal cord injury or stroke with residual neurologic deficit)&#xD;
&#xD;
          -  Subject is seeking obliterative vaginal surgery as treatment for pelvic organ prolapse&#xD;
             (colpocleisis)&#xD;
&#xD;
          -  Subject is not able to conform to the modified dorsal lithotomy position&#xD;
&#xD;
          -  Subject is currently participating in or plans to participate in another device or&#xD;
             drug study during this study&#xD;
&#xD;
          -  Subject has a known sensitivity to any Xenform component&#xD;
&#xD;
          -  Subject has had previous prolapse repair with mesh in the target compartment&#xD;
&#xD;
          -  Subject is planning to undergo a concomitant prolapse repair with use of mesh in the&#xD;
             non-target compartment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Rosenblatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Auburn Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherokee Womens Health Specialist</name>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <zip>30114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acadia Women's Health</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Hanover</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Auburn Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urology Partners</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prime Care of SEO</name>
      <address>
        <city>Dresden</city>
        <state>Ohio</state>
        <zip>43821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Urogynecology</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pelvic Health</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice Research Organization</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Colinas ObGyn</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Women's Health Care</name>
      <address>
        <city>Covington</city>
        <state>Washington</state>
        <zip>98042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 15, 2013</study_first_submitted>
  <study_first_submitted_qc>September 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2013</study_first_posted>
  <results_first_submitted>February 9, 2021</results_first_submitted>
  <results_first_submitted_qc>March 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2021</results_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POP</keyword>
  <keyword>Transvaginal</keyword>
  <keyword>Native Tissue Repair</keyword>
  <keyword>Repair Augmented with Mesh</keyword>
  <keyword>Biologic Graft</keyword>
  <keyword>Pelvic Organ Prolapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT01945580/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study [NCT01917968], 69 subjects from Acell's MatriStem® 522 study &amp; 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 subjects overall</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Xenform</title>
          <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="485"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved out of state</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of state and firmly desired to withdraw. AE still not recovered and not resolved.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family illness - unable to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Weather emergency at time visit due; per sponsor completed study due to being too far out of window</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death in family, then rescheduled but considered too far out of window to bring back</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with 36 month visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>The patient moved.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No data available</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
      <group_list>
        <group group_id="B1">
          <title>Xenform</title>
          <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="228"/>
            <count group_id="B2" value="485"/>
            <count group_id="B3" value="713"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="12.7"/>
                    <measurement group_id="B2" value="61.8" spread="10.5"/>
                    <measurement group_id="B3" value="60.7" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="485"/>
                    <measurement group_id="B3" value="713"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="457"/>
                    <measurement group_id="B3" value="656"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="409"/>
                    <measurement group_id="B3" value="607"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="485"/>
                    <measurement group_id="B3" value="713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="308"/>
                    <measurement group_id="B3" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Recorded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Premenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perimenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="404"/>
                    <measurement group_id="B3" value="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Pelvic Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Success at 36 Months</title>
        <description>The primary endpoint of the study was to achieve non-inferiority of transvaginal repair with Xenform over NTR at 36 months as compared to baseline. Success was based on a composite of objective and subjective measures.&#xD;
Subjective success was achieved if the patient denied symptoms of vaginal bulging per Pelvic Floor Distress Inventory (PFDI-20) question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (&lt; 2).&#xD;
Anatomic success (in the operated compartment):&#xD;
Anterior segment: Leading edge of anterior prolapse was at or above the hymen or Pelvic Organ Prolapse Quantification System (POP-Q) point Ba ≤ 0.&#xD;
Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C &lt; -1/2 TVL) for multi-compartment prolapse or POP-Q point C ≤ 0 for single compartment apical prolapse.&#xD;
No retreatment for POP: no additional surgical treatment for POP in the segment(s) of the vagina treated at the index surgery or no pessary use</description>
        <time_frame>36 Months</time_frame>
        <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Success at 36 Months</title>
          <description>The primary endpoint of the study was to achieve non-inferiority of transvaginal repair with Xenform over NTR at 36 months as compared to baseline. Success was based on a composite of objective and subjective measures.&#xD;
Subjective success was achieved if the patient denied symptoms of vaginal bulging per Pelvic Floor Distress Inventory (PFDI-20) question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (&lt; 2).&#xD;
Anatomic success (in the operated compartment):&#xD;
Anterior segment: Leading edge of anterior prolapse was at or above the hymen or Pelvic Organ Prolapse Quantification System (POP-Q) point Ba ≤ 0.&#xD;
Apical segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C &lt; -1/2 TVL) for multi-compartment prolapse or POP-Q point C ≤ 0 for single compartment apical prolapse.&#xD;
No retreatment for POP: no additional surgical treatment for POP in the segment(s) of the vagina treated at the index surgery or no pessary use</description>
          <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>With type I error of 0.05 and type II error of 0.20 (power 80%), 362 subjects (181 subjects per arm) are needed to detect non-inferiority of transvaginal biologic to native tissue repair, using a margin of 12.0%.</non_inferiority_desc>
            <param_type>Adjusted Difference in Percentages</param_type>
            <param_value>0.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>The propensity adjusted treatment difference of Xenform transvaginal mesh (TVM) minus NTR was estimated and missing data was handled using multiple imputation method.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Device-related and/or Procedure-Related Adverse Events</title>
        <description>Co-primary endpoint of the study was to achieve non-inferiority of transvaginal mesh repair with Xenform to NTR for safety by comparing rates of serious device-related or serious procedure-related complications between baseline and the 36-month time point.</description>
        <time_frame>36 months</time_frame>
        <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Device-related and/or Procedure-Related Adverse Events</title>
          <description>Co-primary endpoint of the study was to achieve non-inferiority of transvaginal mesh repair with Xenform to NTR for safety by comparing rates of serious device-related or serious procedure-related complications between baseline and the 36-month time point.</description>
          <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>With type I error of 0.05 and type II error of 0.10 (power 90%), 308 subjects (154 subjects per arm) are needed to detect non-inferiority with a margin of 11.6%.</non_inferiority_desc>
            <param_type>Adjusted Difference in Percentages</param_type>
            <param_value>2.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
            <estimate_desc>The propensity score adjusted difference in SAE rate of Xenform transvaginal mesh (TVM) vs. NTR was estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mesh Erosion</title>
        <description>Incidence of Mesh Erosion at 36 months</description>
        <time_frame>36 months</time_frame>
        <population>The population includes the 228 subjects in the Xenform arm of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Inclusive</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Measure of Severity</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Measure of Severity</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Measure of Severity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mesh Erosion</title>
          <description>Incidence of Mesh Erosion at 36 months</description>
          <population>The population includes the 228 subjects in the Xenform arm of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="228"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mesh Exposure</title>
        <description>Incidence of mesh exposure at 36 months</description>
        <time_frame>36 Months</time_frame>
        <population>The population includes the 228 subjects in the Xenform arm of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Inclusive</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Measure of Severity</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Measure of Severity</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Measure of Severity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mesh Exposure</title>
          <description>Incidence of mesh exposure at 36 months</description>
          <population>The population includes the 228 subjects in the Xenform arm of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="228"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With de Novo Dyspareunia</title>
        <description>Incidence of de novo dyspareunia at 36 months</description>
        <time_frame>36 months</time_frame>
        <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With de Novo Dyspareunia</title>
          <description>Incidence of de novo dyspareunia at 36 months</description>
          <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Specific Outcomes Measured With the Pelvic Floor Impact Questionnaire (PFIQ-7)]</title>
        <description>Improvement in subject specific outcomes at 36 months compared to baseline [quality of life (QOL) per the Pelvic Floor Impact Questionnaire (PFIQ-7)]&#xD;
The PFIQ-7 is composed of three separate but related assessments: the UIQ-7 addresses the impact of urinary incontinence symptoms, the CRAIQ-7 addresses the impact of colorectal-anal or bowel symptoms, and the POPIQ-7 addresses impact of vaginal and pelvic symptoms. For each question, the low score (0) corresponds to &quot;not at all&quot; and the high score (3) corresponds to &quot;quite a bit&quot;. The scores for the UIQ-7, CRAIQ-7 and POPIQ-7 are additive to yield the final PFIQ-7 score. The scale scores are then added together to get the total PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.&#xD;
Reported score is change from baseline at 36 months.</description>
        <time_frame>36 months</time_frame>
        <population>The 174 Xenform arm participants and 399 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the PFIQ-7 questionnaire at Baseline and 36 months).</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Specific Outcomes Measured With the Pelvic Floor Impact Questionnaire (PFIQ-7)]</title>
          <description>Improvement in subject specific outcomes at 36 months compared to baseline [quality of life (QOL) per the Pelvic Floor Impact Questionnaire (PFIQ-7)]&#xD;
The PFIQ-7 is composed of three separate but related assessments: the UIQ-7 addresses the impact of urinary incontinence symptoms, the CRAIQ-7 addresses the impact of colorectal-anal or bowel symptoms, and the POPIQ-7 addresses impact of vaginal and pelvic symptoms. For each question, the low score (0) corresponds to &quot;not at all&quot; and the high score (3) corresponds to &quot;quite a bit&quot;. The scores for the UIQ-7, CRAIQ-7 and POPIQ-7 are additive to yield the final PFIQ-7 score. The scale scores are then added together to get the total PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.&#xD;
Reported score is change from baseline at 36 months.</description>
          <population>The 174 Xenform arm participants and 399 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the PFIQ-7 questionnaire at Baseline and 36 months).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.2" spread="62.8"/>
                    <measurement group_id="O2" value="-41.9" spread="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Specific Outcomes Measured by the Pelvic Floor Symptoms Per the Pelvic Floor Distress Inventory (PFDI-20)</title>
        <description>Improvement in subject specific outcomes at 36 months compared to baseline [pelvic floor symptoms per the Pelvic Floor Distress Inventory (PFDI-20)]&#xD;
The Pelvic Floor Distress Inventory-20 (PFDI-20) is complimentary to the PFIQ-7 and focuses on symptoms of distress in the same compartmentalized fashion as the PFIQ-7. Like the PFIQ-7, the PFDI-20 consists of three components: Urinary Distress Inventory (UDI; 6 questions), the Pelvic Organ Prolapse Distress Inventory (POPDI; 6 questions), and Colorectal-Anal Distress Inventory (CRADI; 8 questions). The scoring for the PFDI-20 is similar to the PFIQ-7 where each individual component score is summed. The total ranges from 0 to 300 with a higher score indicating a greater impact to QOL (i.e., distress symptoms are more noticeable) and a lower score indicating a lesser impact to QOL (i.e., distress symptoms are less noticeable).&#xD;
The reported result is change from baseline at 36 months.</description>
        <time_frame>36 months</time_frame>
        <population>The 175 Xenform arm participants and 400 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the PFDI-20 questionnaire at Baseline and 36 months).</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Specific Outcomes Measured by the Pelvic Floor Symptoms Per the Pelvic Floor Distress Inventory (PFDI-20)</title>
          <description>Improvement in subject specific outcomes at 36 months compared to baseline [pelvic floor symptoms per the Pelvic Floor Distress Inventory (PFDI-20)]&#xD;
The Pelvic Floor Distress Inventory-20 (PFDI-20) is complimentary to the PFIQ-7 and focuses on symptoms of distress in the same compartmentalized fashion as the PFIQ-7. Like the PFIQ-7, the PFDI-20 consists of three components: Urinary Distress Inventory (UDI; 6 questions), the Pelvic Organ Prolapse Distress Inventory (POPDI; 6 questions), and Colorectal-Anal Distress Inventory (CRADI; 8 questions). The scoring for the PFDI-20 is similar to the PFIQ-7 where each individual component score is summed. The total ranges from 0 to 300 with a higher score indicating a greater impact to QOL (i.e., distress symptoms are more noticeable) and a lower score indicating a lesser impact to QOL (i.e., distress symptoms are less noticeable).&#xD;
The reported result is change from baseline at 36 months.</description>
          <population>The 175 Xenform arm participants and 400 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the PFDI-20 questionnaire at Baseline and 36 months).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.8" spread="58.6"/>
                    <measurement group_id="O2" value="-77.2" spread="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Specific Outcomes Measured by the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)</title>
        <description>Improvement in subject specific outcomes at 36 months compared to baseline [change in sexual functioning per the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)]&#xD;
This is a self-administered questionnaire and the responses are graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Values range from 0 to 48 and a higher score indicates better sexual function.&#xD;
The reported result is change from baseline at 36 months.</description>
        <time_frame>36 months</time_frame>
        <population>The 78 Xenform arm participants and 156 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the PISQ-12 questionnaire at Baseline and 36 months).</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Specific Outcomes Measured by the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)</title>
          <description>Improvement in subject specific outcomes at 36 months compared to baseline [change in sexual functioning per the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)]&#xD;
This is a self-administered questionnaire and the responses are graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Values range from 0 to 48 and a higher score indicates better sexual function.&#xD;
The reported result is change from baseline at 36 months.</description>
          <population>The 78 Xenform arm participants and 156 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the PISQ-12 questionnaire at Baseline and 36 months).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="7.2"/>
                    <measurement group_id="O2" value="4.3" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Specific Outcomes: Pain Measured by the TOMUS Pain Scale</title>
        <description>Improvement in subject specific outcomes at 36 months compared to baseline [pain per the TOMUS pain scale]&#xD;
The TOMUS Pain Score, a visual analog instrument with a scale of 0 (no pain sensation) to 10 (most intense pain sensation imaginable), was used to assess pain associated with surgery for pelvic organ prolapse in this study. There are seven (7) questions each with a maximum score of 10 and a possible score range of 0-70).&#xD;
The reported results are change from baseline at 36 months.</description>
        <time_frame>36 months</time_frame>
        <population>The 175 Xenform arm participants and 399 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the TOMUS pain scale at Baseline and 36 months).</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Specific Outcomes: Pain Measured by the TOMUS Pain Scale</title>
          <description>Improvement in subject specific outcomes at 36 months compared to baseline [pain per the TOMUS pain scale]&#xD;
The TOMUS Pain Score, a visual analog instrument with a scale of 0 (no pain sensation) to 10 (most intense pain sensation imaginable), was used to assess pain associated with surgery for pelvic organ prolapse in this study. There are seven (7) questions each with a maximum score of 10 and a possible score range of 0-70).&#xD;
The reported results are change from baseline at 36 months.</description>
          <population>The 175 Xenform arm participants and 399 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the TOMUS pain scale at Baseline and 36 months).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="8.8"/>
                    <measurement group_id="O2" value="-4.0" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Improvement Measured by the Patient Global Impression of Improvement for Prolapse (PGI-I)</title>
        <description>Assessment of subject's level of improvement, measured by the Patient Global Impression of Improvement for Prolapse (PGI-I)&#xD;
The Patient Global Impression of Improvement (PGI-I) for prolapse symptoms is a validated QOL instrument that assesses patient perception of overall improvement after surgical interventions for POP.12 The scale rates the patient's improvement or worsening of prolapse symptoms relative to baseline. The scale is as follows: 1- Very much better; 2- Much better; 3- A little better; 4- No change; 5- A little worse; 6- Much worse; 7- Very much worse. Assessments were performed at 6-month intervals beginning 6 months after the index procedure.</description>
        <time_frame>36 months</time_frame>
        <population>The 175 Xenform arm participants and 399 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the PGI-I at Baseline and 36 months).</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Improvement Measured by the Patient Global Impression of Improvement for Prolapse (PGI-I)</title>
          <description>Assessment of subject's level of improvement, measured by the Patient Global Impression of Improvement for Prolapse (PGI-I)&#xD;
The Patient Global Impression of Improvement (PGI-I) for prolapse symptoms is a validated QOL instrument that assesses patient perception of overall improvement after surgical interventions for POP.12 The scale rates the patient's improvement or worsening of prolapse symptoms relative to baseline. The scale is as follows: 1- Very much better; 2- Much better; 3- A little better; 4- No change; 5- A little worse; 6- Much worse; 7- Very much worse. Assessments were performed at 6-month intervals beginning 6 months after the index procedure.</description>
          <population>The 175 Xenform arm participants and 399 Native Tissue Repair arm participants are indicative of the available information at the 36 month timepoint (i.e. the number of participants who completed the PGI-I at Baseline and 36 months).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.9"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Re-Intervention or Re-Surgery</title>
        <description>Absence of re-intervention or re-surgery for recurrence or persistence of POP or Xenform exposure/erosion</description>
        <time_frame>36 months</time_frame>
        <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Re-Intervention or Re-Surgery</title>
          <description>Absence of re-intervention or re-surgery for recurrence or persistence of POP or Xenform exposure/erosion</description>
          <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Office-Based Intervention for Recurrent Prolapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Intervention for Recurrent Prolapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Office-Based Intervention for Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Intervention for Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Success</title>
        <description>Surgical success based on the following composite outcome:&#xD;
Subjective success: Patient denied symptoms of vaginal bulging per PFDI-20 question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (˂ 2)&#xD;
Anatomic success (in the operated compartment):&#xD;
Anterior Segment: No anterior prolapse at or beyond the hymen or POP-Q point Ba ˂ 0&#xD;
Apical Segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C ˂ 1/2 TVL) for multi-compartment prolapse or POP-Q point C ˂ 0 for prolapse of the apical compartment alone&#xD;
No retreatment for POP (treated segment): No additional surgical treatment for POP in the segment(s) of the vagina treated at the index surgery or no pessary use since index surgery ('treated segment' refers to the target compartments in this study, which are the anterior and apical compartments)</description>
        <time_frame>36 months</time_frame>
        <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Success</title>
          <description>Surgical success based on the following composite outcome:&#xD;
Subjective success: Patient denied symptoms of vaginal bulging per PFDI-20 question 3, answering &quot;no&quot; or &quot;yes&quot; but &quot;Not at all&quot; bothersome (˂ 2)&#xD;
Anatomic success (in the operated compartment):&#xD;
Anterior Segment: No anterior prolapse at or beyond the hymen or POP-Q point Ba ˂ 0&#xD;
Apical Segment: The vaginal apex did not descend more than one-half into the vaginal canal (i.e., POP-Q point C ˂ 1/2 TVL) for multi-compartment prolapse or POP-Q point C ˂ 0 for prolapse of the apical compartment alone&#xD;
No retreatment for POP (treated segment): No additional surgical treatment for POP in the segment(s) of the vagina treated at the index surgery or no pessary use since index surgery ('treated segment' refers to the target compartments in this study, which are the anterior and apical compartments)</description>
          <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Complications</title>
        <description>Incidence of the following device-related or procedure-related adverse events (AEs): pelvic pain, infection, vaginal shortening, atypical vaginal discharge, neuromuscular problems, vaginal scarring, de novo vaginal bleeding, fistula formation and/or de novo voiding dysfunction.</description>
        <time_frame>36 Months</time_frame>
        <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
        <group_list>
          <group group_id="O1">
            <title>Xenform</title>
            <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Complications</title>
          <description>Incidence of the following device-related or procedure-related adverse events (AEs): pelvic pain, infection, vaginal shortening, atypical vaginal discharge, neuromuscular problems, vaginal scarring, de novo vaginal bleeding, fistula formation and/or de novo voiding dysfunction.</description>
          <population>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study) were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="485"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pelvic pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vaginal shortening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>atypical vaginal discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>neuromuscular problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vaginal scarring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>de novo vaginal bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fistula formation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>de novo voiding dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <desc>412 subjects were screened and 374 subjects were enrolled in the Xenform Postmarket Surveillance Study. 228 subjects were enrolled into the Xenform arm and 146 subjects into the NTR arm. 339 subjects from the AUGS PFD Registry (64 subjects from BSC's Uphold™ LITE 522 study, 69 subjects from Acell's MatriStem® 522 study and 206 subjects from Coloplast's 522 Restorelle® study were pulled into the NTR arm for a total of 485 subjects in the NTR cohort and a total of 713 study subjects overall.</desc>
      <group_list>
        <group group_id="E1">
          <title>Xenform</title>
          <description>Prolapse Repair with Xenform Soft Tissue Repair Matrix&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Prolapse Repair with Native Tissue Only&#xD;
Prolapse Repair: Transvaginal anterior/apical pelvic organ prolapse repair</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Event - NEW</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Cardiac Event - Worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pulmonary Event, Specify - NEW</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation - NEW</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Constipation - Worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Ileus/Bowel Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other, specify type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pelvic Infection/Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pulmonary Event, Specify - NEW</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI), Lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infection - Other, specify type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Ureteral Kink/Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Visceral Organ Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain Tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alzheimers</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Mesh Exposure in Vagina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Difficult Emptying Bladder - NEW</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Hematoma - Retropubic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Stress Incontinence - Worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urinary Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Pain - NEW</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Sensation of Bulge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pulmonary Event, Specify - Worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Bleeding Requiring Blood Transfusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Thrombotic Event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="228"/>
                <counts group_id="E2" subjects_affected="312" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Event - NEW</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Cardiac Event - Worsening</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation - NEW</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Constipation - Worsening</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Fecal Incontinence - NEW</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Fecal Incontinence - Worsening</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Hematoma - Retroperitoneal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Ileus/Bowel Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Neuromuscular Disorder, specify type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Neuromuscular Disorder, specify type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pain, Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other, specify type</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="228"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pelvic Infection/Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pulmonary Event, Specify - NEW</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI), Lower</sub_title>
                <counts group_id="E1" events="39" subjects_affected="26" subjects_at_risk="228"/>
                <counts group_id="E2" events="164" subjects_affected="118" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="228"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Ureteral Kink/Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Visceral Organ Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Buttock Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Neuromuscular Disorder, specify type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasia, Non-Pelvic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuromuscular Disorder, specify type</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Neurovascular Event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Mesh Exposure in Vagina</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Suture Exposure in Vagina</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty Emptying Bladder - NEW</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="228"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Difficulty Emptying Bladder - Worsening</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Mixed Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Mixed Incontinence - Worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Mixed Urinary Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Overactive Bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Stress Incontinence - NEW</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Stress Incontinence - Worsening</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urge Incontinence - NEW</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="228"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urge Incontinence - Worsening</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="228"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Urinary Urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Weak Urinary Stream</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspareunia - NEW (De Novo)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="228"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Dyspareunia - Worsening</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Hematoma - Vaginal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Neuromuscular Disorder, specify type</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pelvic Pain - NEW</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="228"/>
                <counts group_id="E2" events="41" subjects_affected="39" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Pelvic Pain - Worsening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Prolapse</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="228"/>
                <counts group_id="E2" events="93" subjects_affected="88" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Sensation of Bulge</sub_title>
                <counts group_id="E1" events="36" subjects_affected="35" subjects_at_risk="228"/>
                <counts group_id="E2" events="55" subjects_affected="53" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Sensation of Pressure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Atrophy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Bleeding, De Novo</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="228"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Discharge, Atypical</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Scarring</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="228"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vaginal Wall Dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vulvar Itching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Vulvar Lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lichen Sclerosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Skin Condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Tissue Granulation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="228"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Hematoma - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
              <event>
                <sub_title>Other, Specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="228"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="485"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Before publishing, Institution and Investigator shall submit copies of any proposed publication or presentation to Sponsor for review at least sixty (60) days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any Confidential Information or other proprietary information of Sponsor (including trade secrets but not including Results) from the proposed publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Operations</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>952-930-6000</phone>
      <email>teresa.takle-flach@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

